Neuromodulators, dermal fillers, biostimulators, and the longevity question. Label-first, comparison-shaped.
An evidence-based guide to hyperdiluted Radiesse (calcium hydroxylapatite) for skin tightening and body biostimulation, detailing dilution protocols, FDA PMA status, and…
A clinical comparison of Type A (Botox) and Type B (Myobloc) neuromodulators, detailing their distinct molecular targets, duration, pH levels, and FAERS safety data.
A review of the newest FDA dermal filler approvals (Evolysse, saypha MagIQ, Belotero Volume) under product code LMH. Compares chemistry, cross-linking technology, PMA…
A clinical, evidence-first comparison of the only two FDA-approved dermal fillers for hand rejuvenation, reviewing chemical mechanisms, pivotal trials, and safety…
A head-to-head clinical comparison of Xeomin and Jeuveau, analyzing BLA approval histories, purification chemistry, unit conversion ratios, and post-market safety data.
A comprehensive regulatory dossier analyzing AbbVie/Allergan Aesthetics' approvals, BIOCELL textured breast implant recalls, and CoolSculpting and Juvéderm adverse…
An evidence-based pre-treatment guide on blood thinners and supplements for Botox and fillers, analyzing bruising mechanisms, prescription protocols, and technique…
A comprehensive regulatory dossier analyzing Merz Aesthetics' portfolio, Xeomin's BLA registration, Radiesse's and Belotero's PMA history, and Ultherapy PRIME's FDA…
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…
Cosmetic Botox is excluded from HSA/FSA funds, but therapeutic Botox for migraine, hyperhidrosis, or TMJ qualifies with an LMN and proper coding. A detailed regulatory…